References
1. Watson CJ. The ever‐expanding landscape of cancer therapeutic approaches. Wiley Online Library; 2021. p. 6082-6.
2. WHO cancer regional profile [Internet]. World Health Organization. 2020. Available from: https://www.who.int/teams/noncommunicable-diseases/surveillance/data/cancer-profiles.
3. Farhood B, Geraily G, Alizadeh A. Incidence and Mortality of Various Cancers in Iran and Compare to Other Countries: A Review Article. Iran J Public Health. 2018;47(3):309-16.
4. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69(5):363-85.
5. Kaliadzich Z, Zamaro A, Goubkin S, Koulchitsky S, Suziedelis K. Possibilities of Minimization of Side Effects of Anticancer Chemotherapy. J Cancer Sci Treatment. 2019;2(1):84-6.
6. Hauner K, Maisch P, Retz M. Side effects of chemotherapy. Der Urologe Ausg A. 2017;56(4):472-9.
7. Hsu H-C, Tsai S-Y, Wu S-L, Jeang S-R, Ho M-Y, Liou W-S, et al. Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer. Supportive Care in Cancer. 2017;25(11):3457-64.
8. Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A, et al. Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey. Oncotarget. 2017;8(15):24401.
9. Abdalla MEAH, Ali AM, Loong L. The use of complementary and alternative medicine (CAM) among cancer patients at a tertiary hospital in Malaysia. Complementary Therapies in Medicine. 2020;50:102343.
10. Toygar I, Yeşilbalkan ÖU, Kürkütlü M, Aslan A. Complementary and alternative medicines used by cancer patients to cope with chemotherapy-induced constipation. Complementary therapies in clinical practice. 2020;39:101108.
11. Greener M. The hidden problem of herb‐drug interactions. Prescriber. 2016;27(9):22-7.
12. Labidi S, Ennouri S, Rachdi H, El Benna H, Mejri N, Daoud N, et al. Use of complementary and alternative medicine in cancer: a Tunisian single-center experience. Bulletin du cancer. 2020;107(2):209-14.
13. Wode K, Henriksson R, Sharp L, Stoltenberg A, Nordberg JH. Cancer patients’ use of complementary and alternative medicine in Sweden: a cross-sectional study. BMC complementary and alternative medicine. 2019;19(1):1-11.
14. Ong’udi M, Mutai P, Weru I. Study of the use of complementary and alternative medicine by cancer patients at Kenyatta National Hospital, Nairobi, Kenya. Journal of Oncology Pharmacy Practice. 2019;25(4):918-28.
15. Asiimwe JB, Nagendrappa PB, Atukunda EC, Kamatenesi MM, Nambozi G, Tolo CU, et al. Prevalence of the Use of Herbal Medicines among Patients with Cancer: A Systematic Review and Meta-Analysis. Evidence-Based Complementary and Alternative Medicine. 2021;2021.
16. Engdal S, Steinsbekk A, Klepp O, Nilsen OG. Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Supportive Care in Cancer. 2008;16(7):763-9.
17. Cheng C-W, Fan W, Ko S-G, Song L, Bian Z-X. Evidence-based management of herb-drug interaction in cancer chemotherapy. Explore. 2010;6(5):324-9.
18. Sweet E, Dowd F, Zhou M, Standish LJ, Andersen MR. The use of complementary and alternative medicine supplements of potential concern during breast cancer chemotherapy. Evidence-Based Complementary and Alternative Medicine. 2016;2016.
19. Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C. Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. Journal of oncology practice. 2017;13(7):e613-e22.
20. Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb–drug interactions: challenges and opportunities for improved predictions. Drug Metabolism and Disposition. 2014;42(3):301-17.
21. Oga EF, Sekine S, Shitara Y, Horie T. Pharmacokinetic herb-drug interactions: insight into mechanisms and consequences. European journal of drug metabolism and pharmacokinetics. 2016;41(2):93-108.
22. Awortwe C, Makiwane M, Reuter H, Muller C, Louw J, Rosenkranz B. Critical evaluation of causality assessment of herb–drug interactions in patients. British journal of clinical pharmacology. 2018;84(4):679-93.
23. Alsanad SM, Howard RL, Williamson EM. An assessment of the impact of herb-drug combinations used by cancer patients. BMC complementary and alternative medicine. 2016;16(1):1-9.
24. Alsanad SM, Williamson EM, Howard RL. Cancer patients at risk of herb/food supplement–drug interactions: a systematic review. Phytotherapy research. 2014;28(12):1749-55.
25. Meijerman I, Beijnen JH, Schellens JH. Herb‐drug interactions in oncology: focus on mechanisms of induction. The oncologist. 2006;11(7):742-52.
26. Fasinu PS, Rapp GK. Herbal Interaction With Chemotherapeutic Drugs—A Focus on Clinically Significant Findings. Frontiers in oncology. 2019;9:1356.
27. Bazrafshani MS, Khandani BK, Pardakhty A, Tajadini H, Afshar RMP, Moazed V, et al. The prevalence and predictors of using herbal medicines among Iranian cancer patients. Complementary therapies in clinical practice. 2019;35:368-73.
28. McIntyre E, Saliba AJ, Wiener KK, Sarris JJBc, medicine a. Herbal medicine use behaviour in Australian adults who experience anxiety: a descriptive study. 2016;16(1):1-12.
29. Hughes GD, Aboyade OM, Beauclair R, Mbamalu ON, Puoane TRJE-bc, medicine a. Characterizing herbal medicine use for noncommunicable diseases in urban South Africa. 2015;2015.
30. Azizah N, Halimah E, Puspitasari IM, Hasanah ANJJoMH. Simultaneous use of herbal medicines and antihypertensive drugs among hypertensive patients in the community: A review. 2021;14:259.
31. Wolf CP, Rachow T, Ernst T, Hochhaus A, Zomorodbakhsch B, Foller S, et al. Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment. Journal of Cancer Research and Clinical Oncology. 2021:1-13.
32. Bazrafshani MS, Khandani BK, Pardakhty A, Tajadini H, Afshar RMP, Moazed V, et al. The prevalence and predictors of using herbal medicines among Iranian cancer patients. 2019;35:368-73.
33. Welz AN, Emberger-Klein A, Menrad KJBc, medicine a. Why people use herbal medicine: insights from a focus-group study in Germany. 2018;18(1):1-9.
34. Routledge PA, Bracchi RJADRB. Adverse drug reactions to herbal medicines. 2021;331(1):1283-6.
35. Rosenkranz B, Fasinu P, Bouic PJFip. An overview of the evidence and mechanisms of herb–drug interactions. 2012;3:69.
36. Başaran N, Paslı D, Başaran AAJF, Toxicology C. Unpredictable adverse effects of herbal products. 2022;159:112762.
37. Oga EF, Sekine S, Shitara Y, Horie TJEjodm, pharmacokinetics. Pharmacokinetic herb-drug interactions: insight into mechanisms and consequences. 2016;41(2):93-108.
38. Parvez MK, Rishi VJCdm. Herb-drug interactions and hepatotoxicity. 2019;20(4):275-82.
39. Ramos-Esquivel A, Víquez-Jaikel Á, Fernández CJJoop. Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. 2017;13(7):e613-e22.
40. Mahmoud D. The Prevalence of Clinically Relevant Herb-Drug Interactions between Herbal Products and Anti-Cancer Therapy in Older Adults with Cancer. 2021.
41. Citrin D, Gupta D, Birdsall T, Aslam A, Grutsch J, Wodek T, et al. Prevalence of use of herbal therapies in adult cancer patients: Potential for herb-drug interactions. 2005;23(16_suppl):6086-.
42. Van Leeuwen R, Brundel D, Neef C, van Gelder T, Mathijssen R, Burger D, et al. Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs. 2013;108(5):1071-8.
43. Engdal S, Klepp O, Nilsen OGJIct. Identification and exploration of herb-drug combinations used by cancer patients. 2009;8(1):29-36.
44. Ganzera M, Schneider P, Stuppner HJLs. Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes. 2006;78(8):856-61.
45. Blix HS, Viktil KK, Moger TA, Reikvam A. Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharmacy practice. 2010;8(1):50-5.
46. Teo YL, Ho HK, Chan AJBjocp. Metabolism‐related pharmacokinetic drug− drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. 2015;79(2):241-53.
47. Dora NO, Blackburn E, Boles JE, Williams GT, White LJ, Turner SE, et al. Supramolecular self-associating amphiphiles (SSAs) as nanoscale enhancers of cisplatin anticancer activity. 2021;11(23):14213-7.
48. Ackland SP, Michael M, De Souza P, Martin JH, Clarke SJ, Francis K, et al. Science and art of anticancer drug dosing: nine steps to personalised therapy. 2020;50(8):992-6.
49. Darwich A, Ogungbenro K, Hatley OJ, Rostami-Hochaghan AJTCR. Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. 2017.
50. Haefeli WE, Carls AJEoodm, toxicology. Drug interactions with phytotherapeutics in oncology. 2014;10(3):359-77.
51. Köhle C, Bock KWJBp. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. 2009;77(4):689-99.
52. Zanger UM, Schwab MJP, therapeutics. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. 2013;138(1):103-41.
53. Tian D, Hu ZJCDM. CYP3A4-mediated pharmacokinetic interactions in cancer therapy. 2014;15(8):808-17.
54. Fahim SM, Mishuk AU, Cheng N, Hansen R, Calderón AI, Qian JJEOoDS. Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the US Food and Drug Administration Adverse Event Reporting System (FAERS). 2019;18(2):145-52.
55. Engdal S, Nilsen OGJPRAIJDtP, Derivatives TEoNP. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. 2009;23(7):906-12.
56. Levy I, Attias S, Ben-Arye E, Goldstein L, Schiff EJI, medicine e. Potential drug interactions with dietary and herbal supplements during hospitalization. 2017;12(3):301-10.
57. Chi D, Ding D, Zhao Q, Liang X, Wu W, Luo J, et al. Potential herb–drug interactions in community-dwelling older adults in China: the Shanghai Aging Study. Aging Clinical and Experimental Research. 2020;32(12):2677-85.
58. Tan M, Win MT, Khan SAJAAMS. The use of complementary and alternative medicine in chronic pain patients in Singapore: a single-centre study. 2013;42(3):133-7.
59. Rosenberg EI, Genao I, Chen I, Mechaber AJ, Wood JA, Faselis CJ, et al. Complementary and alternative medicine use by primary care patients with chronic pain. 2008;9(8):1065-72.
60. Ha Y, Wang T, Li J, Li J, Lu R, Li J, et al. Herb–drug interaction potential of licorice extract and paclitaxel: A pharmacokinetic study in rats. 2020;45(2):257-64.
61. Zargaran A, Borhani-Haghighi A, Salehi-Marzijarani M, Faridi P, Daneshamouz S, Azadi A, et al. Evaluation of the effect of topical chamomile (Matricaria chamomilla L.) oleogel as pain relief in migraine without aura: a randomized, double-blind, placebo-controlled, crossover study. 2018;39(8):1345-53.
62. Mahboubi MJCTiCP. Mentha spicata as natural analgesia for treatment of pain in osteoarthritis patients. 2017;26:1-4.
63. Djuv A, Nilsen OG, Steinsbekk AJBc, medicine a. The co-use of conventional drugs and herbs among patients in Norwegian general practice: a cross-sectional study. 2013;13(1):1-11.
64. Agbabiaka TB, Spencer NH, Khanom S, Goodman CJBJoGP. Prevalence of drug–herb and drug–supplement interactions in older adults: a cross-sectional survey. 2018;68(675):e711-e7.
65. McLay JS, Stewart D, George J, Rore C, Heys SDJEjocp. Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? 2012;68(5):811-9.
66. Kargozar R, Azizi H, Salari R. A review of effective herbal medicines in controlling menopausal symptoms. Electron Physician. 2017;9(11):5826-33.
67. Pietrzyński Ł, Pysz-Waberski D, Pietrzyńska T, Kliber M, Gisterek IJPMiP. Prevalence of complementary and alternative therapy use by patients with advanced and metastatic cancer. 2022.